{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:49:19Z","timestamp":1793832559462,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG077747"],"award-info":[{"award-number":["AG077747"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK130266"],"award-info":[{"award-number":["R01DK130266"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1053\/j.ajkd.2025.06.019","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T05:18:44Z","timestamp":1758086324000},"page":"803-813","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Targeting Inflammation in CKD"],"prefix":"10.1053","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-3256","authenticated-orcid":false,"given":"Kristen L.","family":"Nowak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Chonchol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1053\/j.ajkd.2025.06.019_bib1","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/s41591-019-0675-0","article-title":"Chronic inflammation in the etiology of disease across the life span","volume":"25","author":"Furman","year":"2019","journal-title":"Nat Med"},{"key":"10.1053\/j.ajkd.2025.06.019_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2020.100130","article-title":"Inflammation and cardiovascular disease: from mechanisms to therapeutics","volume":"4","author":"Alfaddagh","year":"2020","journal-title":"Am J Prev Cardiol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.06.019_bib3","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41581-022-00621-9","article-title":"Targeting innate immunity-driven inflammation in CKD and cardiovascular disease","volume":"18","author":"Speer","year":"2022","journal-title":"Nat Rev Nehrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.06.019_bib4","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3390\/cells12121581","article-title":"The role of inflammation in CKD","volume":"12","author":"Kadatane","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1053\/j.ajkd.2025.06.019_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.kint.2019.01.014","article-title":"Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases","volume":"96","author":"Mulay","year":"2019","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2025.06.019_bib6","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1681\/ASN.2010020143","article-title":"The NLRP3 inflammasome promotes renal inflammation and contributes to CKD","volume":"21","author":"Vilaysane","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2025.06.019_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.atherosclerosis.2017.10.027","article-title":"NLRP3 inflammasome pathways in atherosclerosis","volume":"267","author":"Baldrighi","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1053\/j.ajkd.2025.06.019_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fimmu.2017.00405","article-title":"Interleukin-6 signaling pathway and its role in kidney disease: an update","volume":"8","author":"Su","year":"2017","journal-title":"Front Immunol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.06.019_bib9","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1523-1755.2004.00465.x","article-title":"Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease","volume":"65","author":"Oberg","year":"2004","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2025.06.019_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/01.CIR.0000042700.48769.59","article-title":"Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency","volume":"107","author":"Shlipak","year":"2003","journal-title":"Circulation"},{"issue":"12","key":"10.1053\/j.ajkd.2025.06.019_bib11","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2215\/CJN.03500412","article-title":"Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC","volume":"7","author":"Gupta","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.06.019_bib12","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1046\/j.1523-1755.1999.00422.x","article-title":"Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure","volume":"55","author":"Stenvinkel","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2025.06.019_bib13","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2180373","article-title":"Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome","volume":"2018","author":"Mihai","year":"2018","journal-title":"J Immunol Res"},{"issue":"9","key":"10.1053\/j.ajkd.2025.06.019_bib14","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2215\/CJN.13121215","article-title":"Inflammation and progression of CKD: the CRIC study","volume":"11","author":"Amdur","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.06.019_bib15","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1097\/01.ASN.0000146422.45434.35","article-title":"Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals","volume":"15","author":"Fried","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.06.019_bib16","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/ki.2011.283","article-title":"Markers of inflammation predict the long-term risk of developing chronic kidney disease: a population-based cohort study","volume":"80","author":"Shankar","year":"2011","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2025.06.019_bib23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.ajkd.2018.09.012","article-title":"Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC study","volume":"73","author":"Amdur","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1053\/j.ajkd.2025.06.019_bib24","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jamacardio.2021.3079","article-title":"Interleukin 6 and cardiovascular outcomes in patients with chronic kidney disease and chronic coronary syndrome","volume":"6","author":"Batra","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.06.019_bib25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamacardio.2018.2287","article-title":"Association of Interleukin 6 receptor variant with cardiovascular disease effects of interleukin 6 receptor blocking therapy: a phenome-wide association study","volume":"3","author":"Cai","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"18","key":"10.1053\/j.ajkd.2025.06.019_bib26","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1093\/eurheartj\/ehab107","article-title":"Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality","volume":"42","author":"Schunk","year":"2021","journal-title":"Eur Heart J"},{"issue":"9784","key":"10.1053\/j.ajkd.2025.06.019_bib27","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ajkd.2025.06.019_bib28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"New Engl J Med"},{"issue":"14","key":"10.1053\/j.ajkd.2025.06.019_bib29","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"New Engl J Med"},{"issue":"46","key":"10.1053\/j.ajkd.2025.06.019_bib30","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1093\/eurheartj\/ehac444","article-title":"Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy","volume":"43","author":"Ridker","year":"2022","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1053\/j.ajkd.2025.06.019_bib31","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"De Boer","year":"2022","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1053\/j.ajkd.2025.06.019_bib32","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/jcp.27205","article-title":"The potential therapeutic use of renin-angiotensin system inhibitors in the treatment of inflammatory diseases","volume":"234","author":"Ranjbar","year":"2019","journal-title":"J Cell Physiol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.06.019_bib33","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/ijms26041670","article-title":"Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages","volume":"26","author":"Rykova","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1053\/j.ajkd.2025.06.019_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.06.019_bib37","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1681\/ASN.2016040453","article-title":"IL-1 inhibition and vascular function in CKD","volume":"28","author":"Nowak","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"10.1053\/j.ajkd.2025.06.019_bib43","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","article-title":"Inhibition of Interleukin-1\u03b2 by canakinumab and cardiovascular outcomes in patients with chronic kidney disease","volume":"71","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.06.019_bib45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.34067\/KID.0005862020","article-title":"A phase 1 Randomized dose-escalation study of a human monoclonal antibody to IL-6 in CKD","volume":"2","author":"Nowak","year":"2021","journal-title":"Kidney360"},{"issue":"10289","key":"10.1053\/j.ajkd.2025.06.019_bib46","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.ajkd.2025.06.019_bib47","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jjcc.2023.05.006","article-title":"Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"82","author":"Wada","year":"2023","journal-title":"J Cardiol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.06.019_bib55","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"New Engl J Med"},{"issue":"26","key":"10.1053\/j.ajkd.2025.06.019_bib56","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"De Zeeuw","year":"2013","journal-title":"New Engl J Med"},{"key":"10.1053\/j.ajkd.2025.06.019_bib58","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","article-title":"Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease","volume":"47","author":"Hickson","year":"2019","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1053\/j.ajkd.2025.06.019_bib35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1681\/ASN.2010070760","article-title":"IL-1\u03b2 receptor antagonist reduces inflammation in hemodialysis patients","volume":"22","author":"Hung","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.06.019_bib36","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.kint.2022.06.022","article-title":"A randomized controlled pilot trial of anakinra for hemodialysis inflammation","volume":"102","author":"Dember","year":"2022","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2025.06.019_bib48","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1681\/ASN.2020050595","article-title":"Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1\/2 multicenter, randomized, double-blind, placebo-controlled trial","volume":"32","author":"Pergola","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.06.019_bib50","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1038\/s41591-024-03043-1","article-title":"IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial","volume":"30","author":"Chertow","year":"2024","journal-title":"Nat Med"},{"issue":"5","key":"10.1053\/j.ajkd.2025.06.019_bib38","doi-asserted-by":"crossref","first-page":"702","DOI":"10.2215\/CJN.04360418","article-title":"IL-1 Inhibition and function of the hdl-containing fraction of plasma in patients with stages 3 to 5 CKD","volume":"14","author":"Hung","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.06.019_bib39","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2025.06.019_bib40","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1\u03b2 inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am Heart J"},{"issue":"23","key":"10.1053\/j.ajkd.2025.06.019_bib44","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/eurheartj\/ehz542","article-title":"Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1\u03b2 inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1053\/j.ajkd.2025.06.019_bib49","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra1804281","article-title":"Anemia of inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"New Engl J Med"},{"issue":"26","key":"10.1053\/j.ajkd.2025.06.019_bib51","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"New Engl J Med"},{"issue":"19","key":"10.1053\/j.ajkd.2025.06.019_bib52","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2025.06.019_bib53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41577-024-01075-9","article-title":"Inflammasome components as new therapeutic targets in inflammatory disease","volume":"25","author":"Coll","year":"2025","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.06.019_bib54","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/j.ekir.2021.04.023","article-title":"Chronic inflammation in chronic kidney disease progression: role of Nrf2","volume":"6","author":"Stenvinkel","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1053\/j.ajkd.2025.06.019_bib57","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9372182","article-title":"Activators and inhibitors of NRF2: a review of their potential for clinical development","volume":"2019","author":"Robledinos-Anton","year":"2019","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"10.1053\/j.ajkd.2025.06.019_bib59","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1002\/med.21702","article-title":"Emerging use of senolytics and senomorphics against aging and chronic diseases","volume":"40","author":"Martel","year":"2020","journal-title":"Med Res Rev"},{"issue":"8","key":"10.1053\/j.ajkd.2025.06.019_bib60","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting inflammation in atherosclerosis\u2014from experimental insights to the clinic","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1053\/j.ajkd.2025.06.019_bib61","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"New Engl J Med"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625010182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638625010182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:31:12Z","timestamp":1773815472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638625010182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0272638625010182"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.06.019","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Inflammation in CKD","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}